I'm LongbridgeAI, I can summarize articles.Wedbush initiated coverage of Mentari Therapeutics at Outperform and set a price target of $33.
The price target implies an upside of 79.8% from the Nov 12 close of $18.35.
Explore more price target data and ratings for Mentari Therapeutics on the , and track all previous and future analyst recommendations in the dedicated News Flow.
Select reference data provided by Benzinga. This information is not a recommendation for what you should do personally and does not constitute investment advice.
